We have extensive experience drafting and prosecuting patent applications in the field of engineered peptide therapeutics, gaining insight into the different challenges that working in this area raises as compared to patenting antibody or polypeptide therapeutics. Our experience includes work on portfolios covering approved and candidate peptide therapeutics, such as Lixisenatide, Danegaptide, Glepaglutide and Dasiglucagon.
Many of these challenges revolve around the evolution of an initial wild-type peptide to become a candidate peptide therapeutic, modifying or truncating the wild-type peptide and often incorporating other types of derivatisation and cyclisation to optimise the properties of the therapeutic molecule. This work requires an understanding of underlying biochemistry and chemistry of the molecules.
In addition, the team at Mewburn Ellis working in this area have extensive experience of freedom-to-operate analysis, EPO opposition and appeals and other strategies to manage the competitive landscape, while maximising the protection of the products of the applicants we represent.
-1.png)
.png)
